The recent disclosures of additional LSD1 inhibitors, IMG‐7289, INCB059872, and CC‐90011, under clinical development for SCLC highlight the importance of clarifying the mechanism of action as well as further defining the clinical application of these drugs [6]. This evidence concerns the gene KDM1A and small cell lung carcinoma.